Stingray Healthcare Group is a pan-European cancer care platform focused on radiotherapy. The group operates 32 centres across eight countries and performs approximately 40,000 radiotherapy treatments annually. Since 2021, the group has grown through greenfield developments, bolt-on acquisitions and public-private partnerships (PPPs) with local hospitals.

The business operates in a structurally growing market supported by ageing populations, rising cancer incidence and increasing treatment sophistication. Following the combination of Amethyst and Stingray, the strategic focus is on integration, operational scaling and extending the cancer care offering through nuclear medicine.